Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AVROBIO, Inc. ("AVROBIO" or "the Company") (NASDAQ: AVRO). The investigation concerns whether AVROBIO and certain of its officers and/or directors have violated federal securities laws.


On May 3, 2021, AVROBIO published a report entitled “AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease”. In it, the Company announced that “AVROBIO can no longer pursue an accelerated approval pathway for AVR-RD-01 with the FAB-GT trial as currently designed[.]” Following this news, AVROBIO stock dropped $2.20 per share, or 18%, to close at $9.48 on May 3, 2021.


If you are aware of any facts relating to this investigation, or purchased AVROBIO shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.